Current role of cabozantinib in metastatic castration-resistant prostate cancer (Q38317384)

2 September 2017

1 reference

title

Current role of cabozantinib in metastatic castration-resistant prostate cancer (English)

1 reference

2 September 2017

2

Laurence Albiges

1 reference

2 September 2017

André P Fay

1

1 reference

2 September 2017

Joaquim Bellmunt

series ordinal

3

1 reference

2 September 2017

publication date

14 January 2015

1 reference

Expert Review of Anticancer Therapy

2 September 2017

published in

1 reference

2 September 2017

volume

15

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

151-156

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Cancer treatment and survivorship statistics, 2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Characterising the castration-resistant prostate cancer population: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Enzalutamide in metastatic prostate cancer before chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Radium-223 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Targeting the HGF/Met signaling pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

High expression of the Met receptor in prostate cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Radium-223 in metastatic castration resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1003047

10.1586/14737140.2015.1003047

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference